As far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...

Vedanta’s demerger has left investors awaiting the listing of its four newly carved-out entities, even as the parent stock continues to ris...

Market expert Anand James suggests caution following recent volatility. He notes the Nifty needs to break above 24,140 for a confirmed upsw...

The Indian pharmaceutical sector is poised for significant growth, driven by favorable trade agreements and increasing global demand for ge...

Piramal Pharma shares will be in focus after the US FDA's GMP inspection at its Turbhe facility from February 11-17, 2025, resulting in a F...

Brokerages recently initiated coverage on Delhivery, Quess Corp, and Piramal Pharma. These stocks are expected to return between 19% and 39...

Brokerage firms are bullish on Afcons Infrastructure, Delhivery, and Piramal Pharma, projecting significant upside potential. Investec, Equ...

Chakri Lokapriya highlights a selective approach toward pharma, favoring Cipla and Piramal for potential gains due to specific catalysts li...

Piramal Pharma has broken out from a 6-week consolidation on weekly charts, now trading above key moving averages and is positioned to rise...

The brokerage firm Jefferies assigned buy rating to Piramal Pharma with a target price of Rs 150, implying an upside potential of 20% from ...

Earlier last week, the company obtained a go-ahead from the National Company Law Tribunal (NCLT) for the listing of its equity shares. Furt...

The transaction values the Pharma Business at an enterprise value of USD 2,775 million (over Rs 20,300 crore) with an upside component of u...

The transfer of equity will take place through the Group’s special purpose vehicle Curie, a notice of the combination by the regulator said.

The business house controls both the business segments through a listed entity Piramal Enterprises.

"I would not buy Federal Bank and Piramal Healthcare at this very moment if the market starts stabilising today and starts going up again s...

Devang Visaria, Chief Strategist, Devangvisaria.com in an interview to ET Now said GAIL has given a good breakout and possibly look for odd...

At least two Indian companies, Jubilant Organosys and Hikal Pharma, have dropped out of the race to acquire Pfizer's Ireland unit. However,...